The Analysis Of The Safety And Efficacy And Correlative Factors Of Intravitreal Conbercept Injection In Macular Edema Associated With Branch Retinal Vein Occlusion

Objective:To evaluate the efficacy,safety and correlative factors of intravitreal conbercept injection in macular edema secondary to branch retinal vein occlusion(BRVO).The study observed the changes of best-corrected visual acuity(BCVA),central retina thickness(CRT),photoreceptor layer thickness(PLT)and outer nuclear layer thickness(ONLT)and the correlation between CRT,PLT,ONLT and BCVA after treatment.Methods:This is a self-controled retrospective study.30 eyes of 30 patients with macular edema secondary to BRVO were enrolled.Intravitreal injection of conbercept(0.5mg/0.05ml)was administered to all the patients monthly up to 3 months.Then all patients followed by monthly evaluation and injection pro re nata.The BCVA,CRT,fuqndus photography and fundus fluoresecence angiography(FFA)before and after injections were regarded as efficacy index.The adverse events of the eye and the body at each evaluation were seen as safety indicators.The CRT,PLT and ONLT were considered as efficacy-related indicators.SPSS 19.0 statistical software was adopted for statistical analysis.Results:1.The BCVA was 50.39±9.55 at baseline,and 70.47±12.33,72.72±12.16,70.89±11.74 in Month 1,3 and 6 after treatment.The improvement of BCVA was20.08,22.33 and 20.50 ETDRS letters in Month 1,3 and 6 respectively.Significant difference was found at all three time points(p=0.000,p=0.000,p=0.000).2.The CRT was 477.22±80.02μm at baseline,and 267.47±93.64μm,260.42±86.32μm,260.56±73.28μm in Month 1,3 and 6 after treatment.The desease of CRT was209.75μm,216.81μm and 216.67μm in Month 1,3 and 6 respectively.Significant difference was found at all three time points(p=0.000,p=0.000,p=0.000).3.The PLT at baseline and Month 1,3,6 after injections were as follows:66.06±15.38μm,76.89±11.05μm,78.81±11.61μm and 79.19±11.35μm.Compared with the baseline,the PLT in Month 1,3 and 6 after therapy have significant improvement of10.83μm,12.75μm and 13.14μm respectively(p=0.000,0.000,0.000).4.The ONLT at baseline and Month 1,3,6 after injections were as follows: 411.33 ±78.22μm,193.89±90.14μm,181.72±84.91μm and 180.00±65.95μm.Compared with the baseline,the ONLT in Month 1,3 and 6 after therapy have significant decrease of217.44μm,229.61μm and 231.33μm respectively(p=0.000,0.000,0.000).5.Six months after the conbercept injection,there was a positive correlation between BCVA and PLT(r = 0.486,p=0.003),and there was a negative correlation between BCVA and ONLT(r =-0.402,p = 0.015).In addition,BCVA wasn’t relalated with CRT(r =-0.228,p =0.180).6.The mean number of injection was 3.25±0.50 from baseline to Month 6.The serious adverse events such as retinal detachment and endophthalmitis were not found.Conclusion:1.Intravitreal injection of conbercept can eliminate macular edema due to BRVO and improve the visual function.Intravitreal injection of conbercept demonstrates the safety and efficacy in the treatment of macular edema secondary to BRVO.2.With the intravitreal injection of conbercept,there is a positive correlation between BCVA and PLT,whereas,there is a negative correlation between BCVA and ONLT.In addition,there is no correlation between BCVA and CRT.